Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05482516 | Evaluating Novel Therapies in ctDNA Positive GI Cancers(MRD-GI) | recruiting | Phase 3 | 20 | Georgetown UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05721755 | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | active not recruiting | Phase 3 | 290 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 |
| NCT05883644 | Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)(SIERRA) | active not recruiting | Phase 3 | 111 | AstraZenecaINDUSTRY | 10 | Sep 14, 2026 | clinicaltrials |
| NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | recruiting | Phase 3 | 286 | Jazz PharmaceuticalsINDUSTRY | 25 | Sep 14, 2026 | clinicaltrials |
| NCT06500455 | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | active not recruiting | Phase 3 | 274 | NRG OncologyOTHER | 4 | Sep 14, 2026 | clinicaltrials |
| NCT06514508 | Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients | recruiting | Phase 3 | 60 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06724237 | Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | recruiting | Phase 3 | 294 | Eastern Cooperative Oncology GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT07218146 | A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)(DLLEVATE) | recruiting | Phase 3 | 480 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT07818070 | A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma | not yet recruiting | Phase 3 | 600 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 14, 2026 | clinicaltrials |
| NCT04166409 | A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma | recruiting | Phase 3 | 170 | National Cancer Institute (NCI)NIH | 3 | Sep 11, 2026 | clinicaltrials |
| NCT04191499 | A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer(INAVO120) | active not recruiting | Phase 2 / Phase 3 | 325 | Hoffmann-La RocheINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT04444921 | EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients | active not recruiting | Phase 3 | 205 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04689828 | 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer(PSMAfore) | active not recruiting | Phase 3 | 469 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 11, 2026 | clinicaltrials |
| NCT05187091 | The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas(SWOAR) | recruiting | Phase 3 | 136 | All India Institute of Medical SciencesOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05226598 | Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) | terminated | Phase 3 | 739 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 11, 2026 | clinicaltrials |
| NCT06056830 | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy(CLARIFY) | recruiting | Phase 3 | 383 | Clarity Pharmaceuticals LtdINDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT06091254 | A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma(OLYMPIA-1) | recruiting | Phase 3 | 822 | Regeneron PharmaceuticalsINDUSTRY | 19 | Sep 11, 2026 | clinicaltrials |
| NCT06305754 | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | active not recruiting | Phase 3 | 550 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 11, 2026 | clinicaltrials |
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | recruiting | Phase 3 | 840 | AstraZenecaINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT06784752 | Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET(NETTER-3) | recruiting | Phase 3 | 240 | Novartis PharmaceuticalsINDUSTRY | 12 | Sep 11, 2026 | clinicaltrials |
| NCT07081360 | Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer | recruiting | Phase 3 | 262 | Minia UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07555938 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma(CEVOLUTION) | recruiting | Phase 3 | 380 | Hoffmann-La RocheINDUSTRY | 16 | Sep 11, 2026 | clinicaltrials |
| NCT07673887 | A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer | recruiting | Phase 3 | 570 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 11, 2026 | clinicaltrials |
| NCT07743164 | A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) | not yet recruiting | Phase 3 | 646 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 11, 2026 | clinicaltrials |
| NCT07815574 | iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma(SCOPE Plus) | not yet recruiting | Phase 3 | 550 | Scancell LtdINDUSTRY | 2 | Sep 11, 2026 | clinicaltrials |
| NCT07815665 | A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma(HARMONi-GU1) | recruiting | Phase 2 / Phase 3 | 800 | Summit TherapeuticsINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT00632853 | Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide | completed | Phase 3 | 731 | Alliance for Clinical Trials in OncologyOTHER | 4 | Sep 10, 2026 | clinicaltrials |
| NCT02135042 | Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA | active not recruiting | Phase 2 / Phase 3 | 924 | NRG OncologyOTHER | 8 | Sep 10, 2026 | clinicaltrials |
| NCT02360215 | Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases | completed | Phase 3 | 518 | NRG OncologyOTHER | 2 | Sep 10, 2026 | clinicaltrials |
| NCT02678572 | Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma(FOCUS) | completed | Phase 3 | 102 | Delcath Systems Inc.INDUSTRY | 9 | Sep 10, 2026 | clinicaltrials |
| NCT03180268 | Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | recruiting | Phase 3 | 163 | NRG OncologyOTHER | 5 | Sep 10, 2026 | clinicaltrials |
| NCT03233711 | Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer | active not recruiting | Phase 3 | 344 | National Cancer Institute (NCI)NIH | 2 | Sep 10, 2026 | clinicaltrials |
| NCT04031677 | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma(STRASS2) | recruiting | Phase 3 | 250 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 15 | Sep 10, 2026 | clinicaltrials |
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss(EPIK-B3) | terminated | Phase 3 | 137 | Novartis PharmaceuticalsINDUSTRY | 30 | Sep 10, 2026 | clinicaltrials |
| NCT04493853 | Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency(CAPItello-281) | active not recruiting | Phase 3 | 1,012 | AstraZenecaINDUSTRY | 32 | Sep 10, 2026 | clinicaltrials |
| NCT04759586 | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | active not recruiting | Phase 3 | 244 | National Cancer Institute (NCI)NIH | 4 | Sep 10, 2026 | clinicaltrials |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.(FORTITUDE-102) | terminated | Phase 3 | 515 | AmgenINDUSTRY | 29 | Sep 10, 2026 | clinicaltrials |
| NCT05316935 | GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients | recruiting | Phase 2 / Phase 3 | 80 | Xiaojun ChenOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05438212 | Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | active not recruiting | Phase 3 | 237 | NRG OncologyOTHER | 3 | Sep 10, 2026 | clinicaltrials |
| NCT05448547 | Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer(GrandP/SPCG19) | recruiting | Phase 3 | 980 | Sven LöffelerOTHER | 4 | Sep 10, 2026 | clinicaltrials |
| NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | terminated | Phase 3 | 1,594 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 10, 2026 | clinicaltrials |
| NCT05946213 | Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | recruiting | Phase 3 | 1,209 | NRG OncologyOTHER | 4 | Sep 10, 2026 | clinicaltrials |
| NCT06379113 | GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients | recruiting | Phase 2 / Phase 3 | 29 | Xiaojun ChenOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06561607 | A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer | active not recruiting | Phase 3 | 542 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | active not recruiting | Phase 3 | 726 | mAbxience Research S.L.INDUSTRY | 24 | Sep 10, 2026 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials